

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TenNor Therapeutics (Suzhou) Limited

丹諾醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6872)

(1) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (2) NO DISTRIBUTION OF FINAL DIVIDENDS; AND (3) CHANGES IN COMPOSITION OF SPECIAL COMMITTEE UNDER THE BOARD

I. AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The H Shares of TenNor Therapeutics (Suzhou) Limited (the “**Company**”) were successfully issued and listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on May 22, 2026 (the “**Issuance and Listing**”). In light of the actual circumstances of the Issuance and Listing, the Company has amended the articles of association of TenNor Therapeutics (Suzhou) Limited (the “**Articles of Association**”), and will file the amendments to the Articles of Association with the relevant government or regulatory authorities in China.

Pursuant to the resolutions passed at the 2025 third extraordinary general meeting of the Company, the Shareholders’ meeting of the Company has authorised the board (the “**Board**”) of directors (the “**Directors**”) of the Company and persons authorised by the Board to make corresponding adjustments and amendments to the Articles of Association in accordance with the requirements of domestic or overseas laws and administrative regulations, or the requirements and recommendations of relevant government or regulatory authorities in China and overseas, as well as the actual circumstances of the Issuance and Listing.

Details of the amendments to the Articles of Association are set out as follows:

Before Amendment	After Amendment
Name of Articles of Association: Articles of Association of TenNor Therapeutics (Suzhou) Limited (draft)	Name of Articles of Association: Articles of Association of TenNor Therapeutics (Suzhou) Limited

Before Amendment	After Amendment
<p>Article 3</p> <p>The company obtained the “Filing Notice on Overseas Listing and Domestic Unlisted Shares ‘Full Circulation’” from the China Securities Regulatory Commission (hereinafter referred to as “CSRC”) on January 30, 2026. Approved by the Hong Kong Stock Exchange Limited (hereinafter referred to as “HKEX”) on [Approval Date], it issued up to [number of shares] ordinary H-shares to overseas investors for the first time, with an option to issue up to [number of shares] additional H-shares through an over-allotment. Each H-share has a par value of RMB1.0. The company was listed on the Main Board of the Hong Kong Stock Exchange on [Listing Date].</p>	<p>Article 3</p> <p>The company obtained the “Filing Notice on Overseas Listing and Domestic Unlisted Shares ‘Full Circulation’” from the China Securities Regulatory Commission (hereinafter referred to as “CSRC”) on January 30, 2026. Approved by The Stock Exchange Limited of Hong Kong (hereinafter referred to as “HKEX”) on May 21, 2026, it issued 8,856,000 ordinary H-shares, all being overseas listed foreign shares, to overseas investors for the first time, with an option to issue up to [number of shares] additional H-shares through an over-allotment. Each H-share has a par value of RMB1.0. The company was listed on the Main Board of the HKEX on May 22, 2026.</p>
<p>Article 6</p> <p>Prior to the issuance of H-shares, the company’s registered capital is RMB[●].</p>	<p>Article 6</p> <p>Prior to the issuance of H-shares, the company’s registered capital is RMB43,472,926.</p>
<p>Article 20</p> <p>The Company filed with the CSRC on January 30, 2026 and was approved by the HKEX on [●] year [●] month [●] day to issue no more than [●] shares of foreign shares overseas to overseas investors.</p> <p>If the over-allotment option is not exercised, the total number of shares upon completion of the H-share issuance and listing will be [●] million ordinary shares, comprising [●] non-listed shares and [●] H-shares. Should the over-allotment option be fully exercised, the total number of shares will increase to [●] million ordinary shares, including [●] non-listed shares and [●] H-shares.</p>	<p>Article 20</p> <p>The Company filed with the CSRC on January 30, 2026 and was approved by the HKEX on May 21, 2026 to issue 8,856,000 H-shares shares of foreign shares overseas to overseas investors.</p> <p>If the over-allotment option is not exercised, the total number of shares upon completion of the H-share issuance and listing will be [●] million ordinary shares, comprising [●] non-listed shares and [●] H-shares. Should the over-allotment option be fully exercised, the total number of shares will increase to [●] million ordinary shares, including [●] non-listed shares and [●] H-shares. On May 22, 2026, upon completion of the H-share issuance and listing, the total number of shares was 52,328,926 shares, all being ordinary H-shares.</p>

Before Amendment	After Amendment
Article 128 ... (6) Other functions and powers stipulated by laws and regulations, relevant regulations of the Shanghai Stock Exchange and the articles of association. ...	Article 128 ... (6) Other functions and powers stipulated by laws and regulations, relevant regulations of the Shanghai stock exchange and the articles of association. ...

The full text of the amended Articles of Association is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.tennotherapeutics.com).

II. NO DISTRIBUTION OF FINAL DIVIDENDS

The Board announces that at its meeting held on Monday, June 8, 2026, in accordance with the audited results of the Company's financial report for 2025, the Company Law of the People's Republic of China and the provisions set forth in the Articles of Association, the Board proposes not to distribute final dividends for the year ended December 31, 2025.

III. CHANGES IN COMPOSITION OF SPECIAL COMMITTEE UNDER THE BOARD

Reference is made to the Company's announcement dated June 5, 2026. The Board further announces that Dr. Song Gaoguang, a non-executive Director, has been appointed as a member of the Remuneration and Appraisal Committee of the Board (the "**Remuneration and Appraisal Committee**") with effect from June 8, 2026 until the expiry of the first term of office of the Board. As a result, the Company has re-complied with the relevant requirements regarding the composition of the Remuneration and Appraisal Committee set out in the working rules of the Remuneration and Appraisal Committee.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
*Chairman of the Board, executive Director,
chief executive officer and general manager*

Hong Kong, June 8, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ma Zhenkun as the executive Director; (ii) Dr. Song Gaoguang as the non-executive Director; and (iii) Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping as the independent non-executive Directors.